Medulla oblongata

Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results

Retrieved on: 
星期四, 五月 9, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Clinical Trials, FDA, COYA, University, FTD, Society, Cancer, Viral, Laboratory, Survival, Coya, Conference, GM-CSF, Nebraska Medicine, IND, Granulocyte-macrophage colony-stimulating factor, Pharmacology, Frontotemporal dementia, Patient, Caregiver, Medulla oblongata, Serum, ALS, Diagnosis, PD, Therapy, Pharmaceutical industry

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended March 31, 2024.

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended March 31, 2024.
  • Additionally, clinical data from the previously completed investigator-initiated trial in patients with ALS is also anticipated in the second quarter.
  • 2 investigator-initiated trial involving COYA 301, or low-dose IL-2 alone, is expected in the summer of 2024.
  • As of March 31, 2024, Coya had cash and cash equivalents of $36.0 million.

NRG Energy celebrates $4 million donation milestone to Children’s Hospital of Philadelphia, thanks to its Choose to Give program

Retrieved on: 
星期四, 五月 9, 2024
Managed Care, Other Health, General Health, Other Energy, Utilities, Philanthropy, Oil, Gas, Energy, Hospitals, Fund Raising, Foundation, Other Philanthropy, Health, Learning, MSN, Pulmonary hypertension, Hospital, NRG, CHOP, Communication, Electricity, Growth, Research, FACC, Cardiology, CCRN, Patient, Child, RN, Medulla oblongata, Multimedia, NRG Energy, Division

The milestone was celebrated at the hospital with a check presentation and a tour of the Cardiac Center at CHOP.

Key Points: 
  • The milestone was celebrated at the hospital with a check presentation and a tour of the Cardiac Center at CHOP.
  • To date, NRG has contributed more than $4.2 million through the program, funding more than 30 projects and research initiatives led by experts in CHOP’s Cardiac Center.
  • When NRG customers enroll through the Choose to Give electricity plan, NRG contributes $50 to CHOP.
  • To date, NRG and its customers have contributed more than $15 million to local organizations across the country through this program.

Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

Retrieved on: 
星期五, 四月 26, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Doctor of Philosophy, COYA, Reactive oxygen species, Oxidative stress, Houston Methodist Hospital, HMH, Survival, ROS, Death, Disease, Patient, Medulla oblongata, ALS, Diagnosis, Associate, Therapy, Pharmaceutical industry

The data presented highlights the strong predictive value of oxidative stress biomarker (4-HNE) levels with the rate of disease progression and survival in ALS patients from a longitudinal patient registry cohort.

Key Points: 
  • The data presented highlights the strong predictive value of oxidative stress biomarker (4-HNE) levels with the rate of disease progression and survival in ALS patients from a longitudinal patient registry cohort.
  • Reactive oxygen species (ROS) are generated mainly as byproducts of mitochondrial respiration and are tightly controlled by multiple anti-oxidant mechanisms.
  • In neurodegenerative diseases, such as ALS, when the antioxidant system is overwhelmed by overproduction of ROS, oxidative stress occurs.
  • 4-HNE, an abundant and reactive oxygen species, is thought to exert neuronal toxicity ultimately through formation of toxic protein aggregates, as seen in ALS patients.

Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

Retrieved on: 
星期一, 四月 8, 2024
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Diagnosis, Pharmacology, Conference, Survival, Coya, Associate, Patient, Biomarker, COYA, Medulla oblongata, Death, Society, Doctor of Philosophy, Therapy, Poster, FDA

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board, and Dr. David Beers, Ph.D., Associate Research Professor of Neurology, Houston Methodist, will present updated ALS biomarker data at the upcoming 2nd Annual Johnson Center Symposium in Houston, Texas on April 26, 2024.

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board, and Dr. David Beers, Ph.D., Associate Research Professor of Neurology, Houston Methodist, will present updated ALS biomarker data at the upcoming 2nd Annual Johnson Center Symposium in Houston, Texas on April 26, 2024.
  • The title of the poster is 4-hydroxynonenal (4-HNE) as a Biomarker in ALS.
  • During the Johnson Center Symposium, Dr. Appel will present data correlating 4-HNE levels to bulbar and limb onset ALS.
  • Coya plans to discuss the validation of 4-HNE as a new potential biomarker for ALS and the potential inclusion of 4-HNE as a biomarker in the planned Ph.

Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

Retrieved on: 
星期一, 二月 12, 2024
Master of Science, Diabetes, European Commission, Paratriathlon, FARA, Headache, Research, Movement disorder, BIIB, Diarrhea, Spasm, Drug development, Nausea, Vomiting, Back pain, Biogen, European, Safety, Hearing loss, Civil service commission, Ataxia, Part Two, Fatigue, Life expectancy, European Medicines Agency, Muscle weakness, Patient, Optimism, Medulla oblongata, Clinical trial, Speech, Ageing, Scoliosis, Appetite, FA, Pharmaceutical industry

“Friedreich’s ataxia patients treated with SKYCLARYS in the clinical trial experienced important and clinically meaningful improvements for their daily lives.

Key Points: 
  • “Friedreich’s ataxia patients treated with SKYCLARYS in the clinical trial experienced important and clinically meaningful improvements for their daily lives.
  • At the end of the 48-week study, patients who received SKYCLARYS had significantly improved modified Friedreich Ataxia Rating Scale (mFARS) scores relative to placebo.
  • Biogen is committed to working closely with all stakeholders to ensure that eligible European patients can have access to this treatment.
  • SKYCLARYS is also approved for use in the United States, and Biogen is engaging with regulatory authorities in other regions.

Midland Radio Introduces Ride the Range Heavy-Duty Antennas

Retrieved on: 
星期三, 七月 26, 2023
Harlem Rides the Range, Communication, Medulla oblongata, NMO, Antenna, GMRS, Radio spectrum, Radio, Range, Surveying, Communications satellite, Midland Radio

KANSAS CITY, Mo., July 26, 2023 /PRNewswire/ -- Today Midland Radio, leader of two-way radio communication technology and innovation, introduced a series of four antennas in a new product line, Ride the Range. The new antennas have been optimized for GMRS two-way radio and feature a higher gain with powerful sturdiness, making them the perfect gear for overlanders and off-roaders to add to their setup.

Key Points: 
  • KANSAS CITY, Mo., July 26, 2023 /PRNewswire/ -- Today Midland Radio , leader of two-way radio communication technology and innovation, introduced a series of four antennas in a new product line, Ride the Range.
  • Currently, there aren't many offerings for GMRS bulbar antennas designed with reinforced materials to accommodate rough activities like off-roading or overlanding.
  • These antennas are ideal accessories for those looking for more durable solutions to boost their radio range on devices like the MXT575 and MXT500 MicroMobile® Two-Way Radios.
  • Ride the Range antennas and bundles are now available for purchase.

PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial

Retrieved on: 
星期二, 五月 23, 2023
PTC Therapeutics, Friedreich's ataxia, PTC, Medulla oblongata, EDT, HIV disease progression rates, Patient, Disease, FA, Therapy, News, Conference, Safety, Medical imaging, Pharmaceutical industry

SOUTH PLAINFIELD, N.J., May 23, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today reported topline results from the MOVE-FA trial of vatiquinone in patients with Friedreich ataxia. The study did not meet its primary endpoint of statistically significant change in mFARS score at 72 weeks in the primary analysis population. However, vatiquinone treatment did demonstrate significant benefit on key disease subscales and secondary endpoints. In addition, in the population of subjects that completed the study protocol, significance was reached in the mFARS endpoint and several secondary endpoints.

Key Points: 
  • SOUTH PLAINFIELD, N.J., May 23, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today reported topline results from the MOVE-FA trial of vatiquinone in patients with Friedreich ataxia.
  • However, vatiquinone treatment did demonstrate significant benefit on key disease subscales and secondary endpoints.
  • The MOVE-FA trial enrolled 146 pediatric and adult patients, the majority of which were under 18 years of age.
  • Overall, vatiquinone was demonstrated to be well tolerated, adding to the large volume of safety data collected in other pediatric clinical studies.

Children's Hospital of Philadelphia Receives Multi-Million Dollar Gift from Topolewski Family to Advance Pediatric Heart Valve Research and Establish Endowed Chair in Cardiology

Retrieved on: 
星期四, 五月 18, 2023
Surgeon, Ventricular septal defect, The Center, CHOP, Heart valve repair, Medulla oblongata, FACC, Cardiovascular disease, Research, Cora, Cardiology, Frontier, VSD, Patient, Division, Map, Mortimer, Knowledge, Infant, Hospital, Topolewski v. State, Children's Hospital of Philadelphia, Pharmaceutical industry, Dentistry, Medical device, Nursing, Annals of Pediatric Cardiology, FAAP, MD

PHILADELPHIA, May 18, 2023 /PRNewswire/ -- Children's Hospital of Philadelphia (CHOP) announced that it has received a multi-million dollar gift from the Topolewski family, longstanding supporters of the Cardiac Center at CHOP , to establish the Topolewski Pediatric Heart Valve Center .

Key Points: 
  • PHILADELPHIA, May 18, 2023 /PRNewswire/ -- Children's Hospital of Philadelphia (CHOP) announced that it has received a multi-million dollar gift from the Topolewski family, longstanding supporters of the Cardiac Center at CHOP , to establish the Topolewski Pediatric Heart Valve Center .
  • The Topolewski Pediatric Heart Valve Center brings together a comprehensive team of cardiac surgeons, cardiologists, scientists, researchers, and experts in interventional cardiology and cardiac imaging to revolutionize pediatric cardiac care.
  • This multidisciplinary group takes a coordinated approach and is working to develop precise, evidence-based long-term solutions for infants and children with heart valve disease.
  • As part of the Topolewski family gift, Dr. Jolley will hold the inaugural Topolewski Endowed Chair in Pediatric Cardiology.

Rocket Pharmaceuticals Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

Retrieved on: 
星期二, 五月 9, 2023
Health, FDA, Genetics, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, GMP, Heart, Arrhythmia, Partnership, Doctor of Pharmacy, University, Gene, Arrest, Medulla oblongata, Survival, NYU, FACC, New York University Grossman School of Medicine, Philadelphia, MBA, Child, Disorder, UC San Diego Health, Medication, Arrhythmogenic cardiomyopathy, Patient, Division, Cell, Hospital, Recurrence, Regulation of tobacco by the U.S. Food and Drug Administration, IND, News, Society, Food, Safety, Disease, Pharmaceutical industry, Vaccine, PKP2, FAAP

The current standard of care for patients with PKP2-ACM consists of medical therapy, implantable cardioverter defibrillators (ICDs), and ablations, which are not curative.

Key Points: 
  • The current standard of care for patients with PKP2-ACM consists of medical therapy, implantable cardioverter defibrillators (ICDs), and ablations, which are not curative.
  • The study will assess the impact of RP-A601 on PKP2 myocardial protein expression, cardiac biomarkers, and clinical predictors of life-threatening ventricular arrhythmias and sudden cardiac death.
  • These studies showed that RP-A601 decreased arrhythmias, improved right ventricular morphology and function, and increased survival in PKP2 knockout mice.
  • Rocket is initiating Phase 1 study start-up activities and rapidly working towards first patient treatment.

Accumen Creates Employee Appreciation Day to Honor and Acknowledge Team Members

Retrieved on: 
星期四, 四月 13, 2023
Human resources, Medulla oblongata, 3D, Organization, Physician, Love, Radiographer, Employee Appreciation Day, Environment, Labs, Nursing, Medical imaging

Scottsdale, AZ, April 13, 2023 (GLOBE NEWSWIRE) -- Accumen and 3DR Labs are pleased to announce the commemoration of Employee Appreciation Day.

Key Points: 
  • Scottsdale, AZ, April 13, 2023 (GLOBE NEWSWIRE) -- Accumen and 3DR Labs are pleased to announce the commemoration of Employee Appreciation Day.
  • Employee Appreciation Day took place on Friday, April 7, with official recognition in the National Day Archives.
  • This will now be a day where Accumen and 3DR Labs’ employees celebrate the accomplishments and expertise of team members each year.
  • We are so proud of our team members and what they do each day,” shared Amanda Knox, Sr. Director of Human Resources, Accumen.